PALL-CCA: Retrospective analysis of palliative second-line chemotherapy in cholangiocarcinoma patients

• Conditions: C22; C24; Malignant neoplasm of liver and intrahepatic bile ducts; Malignant neoplasm of other and unspecified parts of biliary tract

• Registration Number: DRKS00030374
• Lead Sponsor: MG Goettingen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-09-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

All patients treated at UMG during 06/2014 to 09/2022

Exclusion Criteria

Age under 18 years

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
overall survival, overall survival under first-line and second-line therapy, retrospective analysis

Secondary Outcome Measures

Name	Time	Method
overall survival under further treatment lines, surgery, and molecular profiles of tumors